mitoxantrone has been researched along with Blood Poisoning in 10 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features." | 9.14 | Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010) |
| "To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)." | 9.09 | Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001) |
| " In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features." | 5.14 | Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010) |
| "To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)." | 5.09 | Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001) |
| "A 64-year-old man with acute myelogenous leukemia (FAB classification, M7) in remission received consolidation chemotherapy with mitoxantrone/cytosine arabinoside." | 4.85 | [Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia]. ( Gondo, H; Kawatani, E; Kishikawa, Y; Kuwahara, N; Matsuishi, E; Mori, D; Osoegawa, K; Sankoda, C, 2009) |
| " Immunoblot analysis revealed iNOS protein expression in four out of six failing hearts from septic patients, whereas no iNOS-protein expression was detected in either non-failing human hearts (n = 6) or failing hearts due to IDC (n = 9), ischemic heart disease (IHD, n = 7), Becker muscular dystrophy (BMD, n = 2) and mitoxantrone-induced toxic cardiomyopathy TCM, n = 1)." | 3.69 | Expression of inducible nitric oxide synthase in failing and non-failing human heart. ( Bleese, NM; Förstermann, U; Nüssler, AK; Scholz, H; Stein, B; Thoenes, M; Tracey, WR, 1996) |
| "Outcome of adults with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) or who relapse soon after initial response is poor." | 2.72 | Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). ( Adamczyk-Cioch, M; Dmoszynska, A; Giebel, S; Holowiecki, J; Jakubas, B; Krawczyk-Kulis, M; Lewandowski, K; Nowak, K; Palynyczko, G; Skotnicki, A, 2006) |
| " The maximal acceptable dosage of mitoxantrone was 10 mg/m2 x 2 due to serious hematologic toxicity." | 2.69 | Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. ( Berinstein, NL; Franssen, E; Haq, R; Sawka, CA, 1999) |
| "67 patients with relapsed or resistant multiple myeloma were randomized to receive either VAD (vincristine, doxorubicin, dexamethasone) or MOD (mitozantrone, vincristine, dexamethasone)." | 2.68 | A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. ( Cawley, JC; Davies, JM; Newland, AC; Pearce, R; Phillips, JK; Reilly, JT; Sherlaw-Johnson, C, 1995) |
| "Bacterial bloodstream infections were the most frequent followed by respiratory tract infections." | 1.91 | Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. ( Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H, 2023) |
| "Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features." | 1.32 | [Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient]. ( Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walti, CS | 2 |
| Halpern, AB | 2 |
| Xie, H | 2 |
| Kiem, ES | 2 |
| Chung, EL | 2 |
| Schonhoff, KG | 2 |
| Huebner, EM | 2 |
| Delaney, C | 2 |
| Liu, C | 2 |
| Pergam, SA | 2 |
| Cheng, GS | 2 |
| Kimball, LE | 2 |
| Leisenring, WM | 2 |
| Boeckh, M | 2 |
| Walter, RB | 2 |
| Hill, JA | 2 |
| Kawatani, E | 1 |
| Kishikawa, Y | 1 |
| Sankoda, C | 1 |
| Kuwahara, N | 1 |
| Mori, D | 1 |
| Osoegawa, K | 1 |
| Matsuishi, E | 1 |
| Gondo, H | 1 |
| Karp, JE | 1 |
| Blackford, A | 1 |
| Smith, BD | 1 |
| Alino, K | 1 |
| Seung, AH | 1 |
| Bolaños-Meade, J | 1 |
| Greer, JM | 1 |
| Carraway, HE | 1 |
| Gore, SD | 1 |
| Jones, RJ | 1 |
| Levis, MJ | 1 |
| McDevitt, MA | 1 |
| Doyle, LA | 1 |
| Wright, JJ | 1 |
| Apostolidou, E | 1 |
| Estey, E | 1 |
| Cortes, J | 1 |
| Garcia-Manero, G | 1 |
| Faderl, S | 1 |
| Thomas, D | 1 |
| Tsimberidou, A | 1 |
| Kantarjian, H | 1 |
| Giles, FJ | 1 |
| Obara, Y | 1 |
| Nagai, T | 1 |
| Mori, M | 1 |
| Ohmine, K | 1 |
| Toshima, M | 1 |
| Komatsu, N | 1 |
| Ozawa, K | 1 |
| Giebel, S | 1 |
| Krawczyk-Kulis, M | 1 |
| Adamczyk-Cioch, M | 1 |
| Jakubas, B | 1 |
| Palynyczko, G | 1 |
| Lewandowski, K | 1 |
| Dmoszynska, A | 1 |
| Skotnicki, A | 1 |
| Nowak, K | 1 |
| Holowiecki, J | 1 |
| Phillips, JK | 1 |
| Sherlaw-Johnson, C | 1 |
| Pearce, R | 1 |
| Davies, JM | 1 |
| Reilly, JT | 1 |
| Newland, AC | 1 |
| Cawley, JC | 1 |
| Thoenes, M | 1 |
| Förstermann, U | 1 |
| Tracey, WR | 1 |
| Bleese, NM | 1 |
| Nüssler, AK | 1 |
| Scholz, H | 1 |
| Stein, B | 1 |
| Haq, R | 1 |
| Sawka, CA | 1 |
| Franssen, E | 1 |
| Berinstein, NL | 1 |
| Alexopoulos, A | 1 |
| Kouroussis, C | 1 |
| Malamos, N | 1 |
| Kakolyris, S | 1 |
| Kalbakis, K | 1 |
| Kosmas, C | 1 |
| Mavroudis, D | 1 |
| Agelaki, S | 1 |
| Vlachonicolis, J | 1 |
| Sarra, E | 1 |
| Rigatos, G | 1 |
| Georgoulias, V | 1 |
1 review available for mitoxantrone and Blood Poisoning
| Article | Year |
|---|---|
[Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacillaceae Infections; Bacillus cereus; Cytarabine; | 2009 |
6 trials available for mitoxantrone and Blood Poisoning
| Article | Year |
|---|---|
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 2010 |
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Human | 2003 |
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease- | 2006 |
A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance; F | 1995 |
Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; D | 1999 |
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
3 other studies available for mitoxantrone and Blood Poisoning
| Article | Year |
|---|---|
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ec | 2004 |
Expression of inducible nitric oxide synthase in failing and non-failing human heart.
Topics: Animals; Cardiomyopathies; Cardiomyopathy, Dilated; Cell Line; Cyclic GMP; Gene Expression; Heart Fa | 1996 |